Tekmira Pharmaceuticals Corp (TKMR) 14.76 $TKMR
Tekmira Jumped Following Update on its Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 4:20PM CST
Tekmira Pharmaceuticals' (TKMR) shares increased almost 9% after it provided updates from phase I/II studies on TKM-PLK1.
TKMR: 14.76 (-0.39), AMGN: 159.89 (+0.60), AMAG: 42.60 (-0.02)
Seeking Alpha's Biotech Weekly: 2014's Approval-Palooza, Ebola In Scotland, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 02, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ACC: 42.09 (+0.73), JNJ: 104.52 (-0.05), NVO: 42.49 (+0.17), OGXI: 2.32 (+0.03), GILD: 94.91 (+0.65), ONVO: 7.29 (+0.04), TKMR: 14.76 (-0.39), TEVA: 56.22 (-1.29), MDXG: 9.74 (-1.79)
Technical Coverage on Biotech Stocks - Arena Pharma, XOMA, Dyax, Mast Therapeutics, and Tekmira Pharma
PR Newswire - Fri Jan 02, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), XOMA Corporation (NASDAQ: XOMA), Dyax Corporation (NASDAQ: DYAX), Mast Therapeutics Inc. (NYSE MKT: MSTX), and Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, December 31, 2014, the NASDAQ Composite ended at 4,736.05, down 0.87%, the Dow Jones Industrial Average declined 0.89%, to finish the day at 17,823.07, and the S&P 500 closed at 2,058.90, down 1.03%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 791.97, down 0.98%, while the index has advanced 7.03% in the previous three months. Register for your complimentary reports on these five stocks at:
MSTX: 0.57 (+0.01), TKMR: 14.76 (-0.39), ARNA: 3.59 (+0.12), DYAX: 14.11 (+0.05), XOMA: 3.55 (-0.04)
Rewards Outweigh Risks: Research Reports on Walgreens, Tekmira, RedHill, Verso, and Pacific Ethanol
PR Newswire - Fri Jan 02, 6:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Walgreens (NASDAQ: WBA), Tekmira (NASDAQ: TKMR), RedHill (NASDAQ: RDHL), Verso (NYSE: VRS), and Pacific Ethanol (NASDAQ: PEIX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
WBA: 76.00 (-0.20), RDHL: 13.79 (+0.46), VRS: 3.37 (-0.06), TKMR: 14.76 (-0.39), PEIX: 10.94 (+0.61)
Meadowbrook and NephroGenex are big market movers
AP - Wed Dec 31, 3:15PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
REN: 1.18 (-0.14), TKMR: 14.76 (-0.39), CVEO: 3.87 (-0.24), CVX: 112.58 (+0.40), MIG: 8.38 (-0.08), TKM.TO: 17.40 (-0.37)
Tekmira Pharmaceuticals (TKMR) Stock Surges Today After Clinical Study Update
at The Street - Wed Dec 31, 1:42PM CST
Shares of Tekmira Pharmaceuticals (TKMR) spiked Wednesday after the company provided an update on a Phase I/II clinical study.
TKMR: 14.76 (-0.39)
Tekmira Pharmaceuticals (TKMR) Is Today's Strong On High Volume Stock
at The Street - Wed Dec 31, 9:10AM CST
Trade-Ideas LLC identified Tekmira Pharmaceuticals (TKMR) as a strong on high relative volume candidate
TKMR: 14.76 (-0.39)
Tekmira progresses in cancer trials
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 9:01AM CST
TKMR: 14.76 (-0.39)
Tekmira Provides Update on TKM-PLK1 Phase I/II Clinical Study in Patients With Advanced Gastrointestinal Neuroendocrine Tumors and Adrenocortical Carcinoma
GlobeNewswire - Wed Dec 31, 8:30AM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today provided a status update on the Phase I/II clinical study in patients with advanced Gastrointestinal Neuroendocrine Tumors (GI-NET) and Adrenocortical Carcinoma (ACC).
TKMR: 14.76 (-0.39), TKM.TO: 17.40 (-0.37)
Critical Alerts For Advanced Micro Devices, Novo Nordisk, Tekmira Pharmaceuticals, ITT Education and Workday Released By InvestorsObserver
PR Newswire - Tue Dec 30, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AMD, NVO, TKMR, ESI and WDAY.
NVO: 42.49 (+0.17), ESI: 9.35 (-0.26), AMD: 2.69 (+0.02), WDAY: 80.41 (-1.20), TKMR: 14.76 (-0.39)
Wall Street Breakfast: Oil Prices Hit Fresh 5-Year Lows
Wall Street Breakfast - at Seeking Alpha - Tue Dec 30, 5:31AM CST
BCRX: 12.14 (-0.02), CPS: 58.01 (+0.13), TKMR: 14.76 (-0.39), SNE: 20.56 (+0.09), TM: 125.67 (+0.19), MLNK: 3.60 (-0.15), EQC: 26.04 (+0.37), GOOG: 524.81 (-1.59), NEWM: 23.29 (-0.34), PBR: 6.76 (-0.54), SPY: 205.43 (-0.11), QQQ: 102.94 (-0.31), GOOGL: 529.55 (-1.11), ARCP: 9.27 (+0.22), MSFT: 46.76 (+0.31), AAPL: 109.33 (-1.05), SHOS: 12.70 (-0.45)
Scotland confirms Ebola case
Seeking Alpha - at Seeking Alpha - Tue Dec 30, 12:53AM CST
INO: 9.32 (+0.14), BCRX: 12.14 (-0.02), HEB: 0.25 (unch), NLNK: 43.65 (+3.90), TKMR: 14.76 (-0.39)
NewLink and Merck Get a $30M Contract for Ebola Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 11:00AM CST
NewLink Genetics and Merck announced that the BARDA has awarded a $30 million contract for their Ebola vaccine candidate, rVSV-EBOV.
MRK: 57.19 (+0.40), NLNK: 43.65 (+3.90), TKMR: 14.76 (-0.39), GSK: 42.37 (-0.37)
Viral Investing: Ebola Drug Makers' Varied Strategies
at Investor's Business Daily - Fri Dec 26, 3:09PM CST
The stock market is an organism that strives to identify opportunity in every crisis. That held true in the late summer and early fall, when the outbreak of Ebola virus in West Africa reached crisis proportions in Guinea, Liberia and Sierra Leone....
BBP: 26.48 (+0.36), INO: 9.32 (+0.14), JNJ: 104.52 (-0.05), BBC: 28.40 (+0.66), BCRX: 12.14 (-0.02), CMRX: 41.78 (+1.52), MRK: 57.19 (+0.40), SRPT: 14.94 (+0.47), NLNK: 43.65 (+3.90), TKMR: 14.76 (-0.39), GSK: 42.37 (-0.37)
5 Best Performing Stocks of the Nasdaq in 2014 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 9:58AM CST
The tech-laden Nasdaq Composite index enjoyed a bull run this year banking on broad based gains among Internet and bio-tech stocks, better-than expected GDP numbers and Fed's assurance about the economy.
CMRX: 41.78 (+1.52), SWKS: 73.32 (+0.61), IBM: 162.06 (+1.62), CHL: 58.49 (-0.33), HZNP: 12.80 (-0.09), TKMR: 14.76 (-0.39), GOOGL: 529.55 (-1.11), MSFT: 46.76 (+0.31), AAPL: 109.33 (-1.05), PLNR: 8.36 (-0.01), AVGO: 100.09 (-0.50), RFMD: 16.59 (-0.35)
Tekmira Pharmaceuticals
at Investor's Business Daily - Mon Dec 22, 5:30PM CST
Tekmira Pharmaceuticals (TKMR) will supply 100 courses of its experimental Ebola treatment for clinical studies in W. Africa, which will be conducted by a global research group that includes Oxford Univ. The studies are expected to start in early...
TKMR: 14.76 (-0.39)
University of Oxford to make Tekmira Ebola drug for clinical trial
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 9:38AM CST
TKMR: 14.76 (-0.39)
Tekmira Establishes Manufacturing and Clinical Trial Agreement to Provide TKM-Ebola-Guinea for Clinical Studies in West Africa
GlobeNewswire - Mon Dec 22, 9:34AM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that the Company has entered into a Manufacturing and Clinical Trial Agreement with the University of Oxford to provide the new TKM-Ebola-Guinea therapeutic product for clinical studies in West Africa. The studies are expected to commence early next year, subject to finalization of a suitable clinical protocol.
TKMR: 14.76 (-0.39), TKM.TO: 17.40 (-0.37)
Tekmira Receives Clearance to Conduct a Phase I Clinical Study With TKM-HBV
GlobeNewswire - Mon Dec 22, 7:45AM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that it has received a No Objection Letter from Health Canada regarding its Clinical Trial Application, allowing the Company to proceed with a Phase I clinical trial with TKM-HBV, a therapeutic agent designed to treat patients chronically infected with hepatitis B virus (HBV).
TKMR: 14.76 (-0.39), TKM.TO: 17.40 (-0.37)
Tekmira Jumped Following Update on its Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 4:20PM CST
Tekmira Pharmaceuticals' (TKMR) shares increased almost 9% after it provided updates from phase I/II studies on TKM-PLK1.
TKMR: 14.76 (-0.39), AMGN: 159.89 (+0.60), AMAG: 42.60 (-0.02)
Seeking Alpha's Biotech Weekly: 2014's Approval-Palooza, Ebola In Scotland, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 02, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ACC: 42.09 (+0.73), JNJ: 104.52 (-0.05), NVO: 42.49 (+0.17), OGXI: 2.32 (+0.03), GILD: 94.91 (+0.65), ONVO: 7.29 (+0.04), TKMR: 14.76 (-0.39), TEVA: 56.22 (-1.29), MDXG: 9.74 (-1.79)
Technical Coverage on Biotech Stocks - Arena Pharma, XOMA, Dyax, Mast Therapeutics, and Tekmira Pharma
PR Newswire - Fri Jan 02, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), XOMA Corporation (NASDAQ: XOMA), Dyax Corporation (NASDAQ: DYAX), Mast Therapeutics Inc. (NYSE MKT: MSTX), and Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, December 31, 2014, the NASDAQ Composite ended at 4,736.05, down 0.87%, the Dow Jones Industrial Average declined 0.89%, to finish the day at 17,823.07, and the S&P 500 closed at 2,058.90, down 1.03%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 791.97, down 0.98%, while the index has advanced 7.03% in the previous three months. Register for your complimentary reports on these five stocks at:
MSTX: 0.57 (+0.01), TKMR: 14.76 (-0.39), ARNA: 3.59 (+0.12), DYAX: 14.11 (+0.05), XOMA: 3.55 (-0.04)
Rewards Outweigh Risks: Research Reports on Walgreens, Tekmira, RedHill, Verso, and Pacific Ethanol
PR Newswire - Fri Jan 02, 6:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Walgreens (NASDAQ: WBA), Tekmira (NASDAQ: TKMR), RedHill (NASDAQ: RDHL), Verso (NYSE: VRS), and Pacific Ethanol (NASDAQ: PEIX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
WBA: 76.00 (-0.20), RDHL: 13.79 (+0.46), VRS: 3.37 (-0.06), TKMR: 14.76 (-0.39), PEIX: 10.94 (+0.61)
Meadowbrook and NephroGenex are big market movers
AP - Wed Dec 31, 3:15PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
REN: 1.18 (-0.14), TKMR: 14.76 (-0.39), CVEO: 3.87 (-0.24), CVX: 112.58 (+0.40), MIG: 8.38 (-0.08), TKM.TO: 17.40 (-0.37)
Tekmira Pharmaceuticals (TKMR) Stock Surges Today After Clinical Study Update
at The Street - Wed Dec 31, 1:42PM CST
Shares of Tekmira Pharmaceuticals (TKMR) spiked Wednesday after the company provided an update on a Phase I/II clinical study.
TKMR: 14.76 (-0.39)
Tekmira Pharmaceuticals (TKMR) Is Today's Strong On High Volume Stock
at The Street - Wed Dec 31, 9:10AM CST
Trade-Ideas LLC identified Tekmira Pharmaceuticals (TKMR) as a strong on high relative volume candidate
TKMR: 14.76 (-0.39)
Tekmira progresses in cancer trials
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 9:01AM CST
TKMR: 14.76 (-0.39)
Tekmira Provides Update on TKM-PLK1 Phase I/II Clinical Study in Patients With Advanced Gastrointestinal Neuroendocrine Tumors and Adrenocortical Carcinoma
GlobeNewswire - Wed Dec 31, 8:30AM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today provided a status update on the Phase I/II clinical study in patients with advanced Gastrointestinal Neuroendocrine Tumors (GI-NET) and Adrenocortical Carcinoma (ACC).
TKMR: 14.76 (-0.39), TKM.TO: 17.40 (-0.37)
Critical Alerts For Advanced Micro Devices, Novo Nordisk, Tekmira Pharmaceuticals, ITT Education and Workday Released By InvestorsObserver
PR Newswire - Tue Dec 30, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AMD, NVO, TKMR, ESI and WDAY.
NVO: 42.49 (+0.17), ESI: 9.35 (-0.26), AMD: 2.69 (+0.02), WDAY: 80.41 (-1.20), TKMR: 14.76 (-0.39)
Wall Street Breakfast: Oil Prices Hit Fresh 5-Year Lows
Wall Street Breakfast - at Seeking Alpha - Tue Dec 30, 5:31AM CST
BCRX: 12.14 (-0.02), CPS: 58.01 (+0.13), TKMR: 14.76 (-0.39), SNE: 20.56 (+0.09), TM: 125.67 (+0.19), MLNK: 3.60 (-0.15), EQC: 26.04 (+0.37), GOOG: 524.81 (-1.59), NEWM: 23.29 (-0.34), PBR: 6.76 (-0.54), SPY: 205.43 (-0.11), QQQ: 102.94 (-0.31), GOOGL: 529.55 (-1.11), ARCP: 9.27 (+0.22), MSFT: 46.76 (+0.31), AAPL: 109.33 (-1.05), SHOS: 12.70 (-0.45)
Scotland confirms Ebola case
Seeking Alpha - at Seeking Alpha - Tue Dec 30, 12:53AM CST
INO: 9.32 (+0.14), BCRX: 12.14 (-0.02), HEB: 0.25 (unch), NLNK: 43.65 (+3.90), TKMR: 14.76 (-0.39)
NewLink and Merck Get a $30M Contract for Ebola Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 11:00AM CST
NewLink Genetics and Merck announced that the BARDA has awarded a $30 million contract for their Ebola vaccine candidate, rVSV-EBOV.
MRK: 57.19 (+0.40), NLNK: 43.65 (+3.90), TKMR: 14.76 (-0.39), GSK: 42.37 (-0.37)
Viral Investing: Ebola Drug Makers' Varied Strategies
at Investor's Business Daily - Fri Dec 26, 3:09PM CST
The stock market is an organism that strives to identify opportunity in every crisis. That held true in the late summer and early fall, when the outbreak of Ebola virus in West Africa reached crisis proportions in Guinea, Liberia and Sierra Leone....
BBP: 26.48 (+0.36), INO: 9.32 (+0.14), JNJ: 104.52 (-0.05), BBC: 28.40 (+0.66), BCRX: 12.14 (-0.02), CMRX: 41.78 (+1.52), MRK: 57.19 (+0.40), SRPT: 14.94 (+0.47), NLNK: 43.65 (+3.90), TKMR: 14.76 (-0.39), GSK: 42.37 (-0.37)
5 Best Performing Stocks of the Nasdaq in 2014 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 9:58AM CST
The tech-laden Nasdaq Composite index enjoyed a bull run this year banking on broad based gains among Internet and bio-tech stocks, better-than expected GDP numbers and Fed's assurance about the economy.
CMRX: 41.78 (+1.52), SWKS: 73.32 (+0.61), IBM: 162.06 (+1.62), CHL: 58.49 (-0.33), HZNP: 12.80 (-0.09), TKMR: 14.76 (-0.39), GOOGL: 529.55 (-1.11), MSFT: 46.76 (+0.31), AAPL: 109.33 (-1.05), PLNR: 8.36 (-0.01), AVGO: 100.09 (-0.50), RFMD: 16.59 (-0.35)
Tekmira Pharmaceuticals
at Investor's Business Daily - Mon Dec 22, 5:30PM CST
Tekmira Pharmaceuticals (TKMR) will supply 100 courses of its experimental Ebola treatment for clinical studies in W. Africa, which will be conducted by a global research group that includes Oxford Univ. The studies are expected to start in early...
TKMR: 14.76 (-0.39)
University of Oxford to make Tekmira Ebola drug for clinical trial
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 9:38AM CST
TKMR: 14.76 (-0.39)
Tekmira Establishes Manufacturing and Clinical Trial Agreement to Provide TKM-Ebola-Guinea for Clinical Studies in West Africa
GlobeNewswire - Mon Dec 22, 9:34AM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that the Company has entered into a Manufacturing and Clinical Trial Agreement with the University of Oxford to provide the new TKM-Ebola-Guinea therapeutic product for clinical studies in West Africa. The studies are expected to commence early next year, subject to finalization of a suitable clinical protocol.
TKMR: 14.76 (-0.39), TKM.TO: 17.40 (-0.37)
Tekmira Receives Clearance to Conduct a Phase I Clinical Study With TKM-HBV
GlobeNewswire - Mon Dec 22, 7:45AM CST
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that it has received a No Objection Letter from Health Canada regarding its Clinical Trial Application, allowing the Company to proceed with a Phase I clinical trial with TKM-HBV, a therapeutic agent designed to treat patients chronically infected with hepatitis B virus (HBV).
TKMR: 14.76 (-0.39), TKM.TO: 17.40 (-0.37)
